Biovail discontinues BVF-324

Biovail Corp. (TSX:BVF; NYSE:BVF) disclosed in its 2Q10 earnings call that it discontinued development of BVF-324 to treat premature ejaculation due to slow enrollment in Phase III trials and a reevaluation of the product's commercial potential. Biovail acquired exclusive, worldwide rights to the tramadol formulation from an undisclosed party in 2007. Further details were not disclosed. ...